Completed
PHASE4
INTERVENTIONAL
NCT05564039
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC
Name:
Dulaglutide
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Change From Baseline in HbA1c
TimeFrame:
Baseline, Week 40
Description:
HbA1c is the glycated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least squares (LS) mean was calculated using mixed model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Number of Background OAMs Group 1 + Dulaglutide Dose at Screening + Geographic Region 1 + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
Trial Information
NCT ID
NCT05564039
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025